



**POLICY:** Oncology (Injectable – Microtubule Inhibitor) – Paclitaxel Albumin-Bound Products Utilization Management Medical Policy

- Abraxane® (paclitaxel albumin-bound suspension, intravenous infusion – Celgene, generic)

**EFFECTIVE DATE:** 1/1/2022

**REVIEW DATE:** 10/15/2025

**COVERAGE CRITERIA FOR:** UCare Medical Assistance and Exchange Plans Only (PMAP, Connect, MSC+, MnCare, all Individual and Family Plans)

---

## OVERVIEW

Paclitaxel albumin-bound, a microtubule inhibitor, is indicated for the following uses:<sup>1</sup>

- **Breast cancer**, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline (unless contraindicated).
- **Non-small cell lung cancer (NSCLC)**, in combination with carboplatin, for the first-line treatment of locally advanced or metastatic disease in patients who are not candidates for curative surgery or radiation therapy.
- **Pancreatic adenocarcinoma**, in combination with gemcitabine, for the first-line treatment of patients with metastatic disease.

Limited dosing is available regarding use of paclitaxel albumin-bound for conditions listed under “Other Uses with Supportive Evidence”. Recommended doses in the product label for approved uses include 100 mg/m<sup>2</sup> administered by intravenous (IV) infusion three times in each 21-day cycle, 125 mg/m<sup>2</sup> administered by IV infusion three times in each 28-day cycle, and 260 mg/m<sup>2</sup> administered by IV infusion once every 21 days.<sup>1</sup>

## Guidelines

Paclitaxel albumin-bound is addressed in a variety of National Comprehensive Cancer Network (NCCN) guidelines:

- **Breast cancer:** Guidelines (version 4.2025 – April 17, 2025) recommend paclitaxel albumin-bound in combination with Keytruda® (pembrolizumab intravenous infusion) as one of the “Preferred” first-line regimens for programmed death-ligand 1 (PD-L1) positive triple-negative breast cancer (category 1).<sup>2,3</sup> It can be used or subsequent therapy (second or third-line) if no prior use of immunotherapy. Paclitaxel albumin-bound, as a single agent or in combination with carboplatin, is recommended for recurrent, unresectable (local or regional) or metastatic HER2-negative disease; and in combination with trastuzumab for recurrent, unresectable (local or regional) or metastatic HER2-positive disease. It is noted that paclitaxel albumin-bound may be substituted for paclitaxel or docetaxel due to medical necessity (i.e., hypersensitivity reaction).
- **NSCLC:** Guidelines (version 8.2025 – August 15, 2025) recommend paclitaxel albumin-bound as first-line therapy for recurrent, advanced, or metastatic PD-L1 expression positive ( $\geq 1\%$ ) tumors that are negative for *EGFR*, *ALK*, *ROS1*, *BRAF*, *NTRK1/2/3*, *MET*, and *RET*, in combination with Keytruda and carboplatin for squamous cell histology, and in combination with carboplatin and Tecentriq® (atezolizumab intravenous infusion) for non-squamous cell histology.<sup>3,4</sup> Paclitaxel

albumin-bound is recommended for the treatment of recurrent, advanced, or metastatic squamous cell or nonsquamous cell disease, as a single-agent or in combination with carboplatin with or without Keytruda or Tecentriq, in a variety of clinical situations.

- **Pancreatic adenocarcinoma:** Guidelines (version 2.2025 – February 3, 2025) recommend therapy with paclitaxel albumin-bound in a variety of settings.<sup>3,5</sup> This includes neoadjuvant therapy; first-line or induction therapy followed by chemoradiation; first-line for metastatic disease (category 1); and in second-line settings after recurrence.
- **Other Uses with Supportive Evidence:** The NCCN Compendium supports the use of paclitaxel albumin-bound for the following conditions: Kaposi sarcoma, intra or extrahepatic cholangiocarcinoma, cervical cancer, ampullary adenocarcinoma, gallbladder cancer, endometrial carcinoma, melanoma, ovarian/fallopian/primary peritoneal cancer, small bowel adenocarcinoma, vaginal cancer, and uveal melanoma.<sup>6-15</sup> The criteria are consistent with the guideline recommendations.

## POLICY STATEMENT

Prior Authorization is recommended for medical benefit coverage of paclitaxel albumin-bound. Approval is recommended for those who meet the **Criteria** and **Dosing** for the listed indications. Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of patients treated with paclitaxel albumin-bound as well as the monitoring required for adverse events and long-term efficacy, approval requires paclitaxel albumin-bound to be prescribed by or in consultation with a physician who specializes in the condition being treated.

**Automation:** None.

## RECOMMENDED AUTHORIZATION CRITERIA

Coverage of paclitaxel albumin-bound is recommended in those who meet one of the following criteria:

### FDA-Approved Indications

---

1. **Breast Cancer.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):
  - A) Patient is  $\geq$  18 years of age; AND
  - B) Patient meets ONE of the following criteria (i or ii):
    - i. Patient has recurrent or metastatic breast cancer and meets ONE of the following criteria (a, b, or c):
      - a) Patient has human epidermal growth factor receptor 2 (HER2)-negative disease; OR
      - b) Patient has triple-negative breast cancer; OR
      - c) Patient has human epidermal growth factor receptor 2 (HER2)-positive disease and the medication will be used in combination with trastuzumab; OR
    - ii. Patient has had a hypersensitivity reaction to paclitaxel or docetaxel; AND
  - C) The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve ONE of the following (A or B):

- A) Approve up to  $260 \text{ mg/m}^2$  administered as an intravenous infusion no more frequently than once every 3 weeks; OR

**B)** Approve up to 125 mg/m<sup>2</sup> administered as an intravenous infusion no more frequently than three times in each 28-day cycle.

---

**2. Non-Small Cell Lung Cancer (NSCLC).** Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):

**A)** Patient is  $\geq$  18 years of age; AND

**B)** Patient has recurrent, advanced, or metastatic non-small cell lung cancer (NSCLC); AND

**C)** Patient meets ONE of the following criteria (i, ii, or iii):

- i.** Patient meets BOTH of the following (a and b):
  - a)** The tumor is negative for the following actionable biomarkers: epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R, anaplastic lymphoma kinase (ALK), RET, and ROS1; AND
  - b)** The medication is used as initial or subsequent therapy; OR
- ii.** The patient meets BOTH of the following (a and b):
  - a)** The medication will be used as subsequent therapy; AND
  - b)** The tumor is positive for one of the following [(1), (2), (3), (4), or (5)]:
    - (1)** Epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation; OR
    - (2)** Epidermal growth factor receptor (EGFR) S768I, L861Q, and/or G719X mutation; OR
    - (3)** RET rearrangement positive; OR
    - (4)** Anaplastic lymphoma kinase (ALK) rearrangement positive; OR
    - (5)** ROS1 rearrangement positive; OR
- iii.** Patient has experienced a hypersensitivity reaction after receiving paclitaxel or docetaxel; AND

**D)** The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve up to 100 mg/m<sup>2</sup> administered as an intravenous infusion no more frequently than three times in each 21-day cycle.

---

**3. Pancreatic Adenocarcinoma.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):

**A)** Patient is  $\geq$  18 years of age; AND

**B)** The medication will be used in combination with gemcitabine; AND

**C)** The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve up to 125 mg/m<sup>2</sup> as an intravenous infusion no more frequently than three times in each 28-day cycle.

## Other Uses with Supportive Evidence

---

**4. Ampullary Adenocarcinoma.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):

**A)** Patient is  $\geq$  18 years of age; AND

**B)** The medication will be used in combination with gemcitabine; AND

**C)** The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve up to 125 mg/m<sup>2</sup> as an intravenous infusion no more frequently than three times in each 28-day cycle.

---

---

**5. Biliary Tract Cancer.** Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):

- A)** Patient is  $\geq$  18 years of age; AND
- B)** Patient meets ONE of the following (i or ii):
  - i.** Patient meets BOTH of the following (a and b):
    - 1. Patient has gallbladder cancer; AND
    - 2. The medication is used as neoadjuvant therapy; OR
  - ii.** Patient meets BOTH of the following (a and b):
    - 1. Patient has unresectable, resected gross residual, or metastatic disease; AND
    - 2. Patient has ONE of the following conditions [(1), (2) or (3)]:
      - (1) Gallbladder cancer; OR
      - (2) Intrahepatic cholangiocarcinoma; OR
      - (3) Extrahepatic cholangiocarcinoma; AND
- C)** The medication is used in combination with gemcitabine; AND
- D)** The medication is prescribed by or in consultation with an oncologist.

**Dosing:** Approve ONE of the following (A or B):

- A)** Approve up to  $125 \text{ mg/m}^2$  administered as an intravenous infusion given no more frequently than twice every 21 days; OR
- B)** Approve up to  $125 \text{ mg/m}^2$  administered as an intravenous infusion given no more frequently than three times every 28 days.

---

**6. Cervical Cancer.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):

- A)** Patient is  $\geq$  18 years of age; AND
- B)** The medication will be used as subsequent therapy; AND
- C)** The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve up to  $125 \text{ mg/m}^2$  as an intravenous infusion no more frequently than three times in each 28-day cycle.

---

**7. Endometrial Carcinoma.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):

- A)** Patient is  $\geq$  18 years of age; AND
- B)** Patient has recurrent or metastatic disease; AND
- C)** The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve doses between  $100 \text{ mg/m}^2$  and  $260 \text{ mg/m}^2$  administered as an intravenous infusion given no more frequently than once every 21 days.

---

**8. Kaposi Sarcoma.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):

- A)** Patient is  $\geq$  18 years of age; AND
- B)** Patient has tried at least one systemic chemotherapy; AND
  - Note:** Examples of systemic chemotherapy are doxorubicin and paclitaxel.
- C)** The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve 100 mg administered as an intravenous infusion no more frequently than three times in each 28-day cycle.

---

**9. Melanoma.** Approve for 1 year if the patient meets ALL of the following (A, B, C, and D):

- A) Patient is  $\geq$  18 years of age; AND
- B) Patient has unresectable or metastatic melanoma; AND
- C) At least one other systemic therapy for melanoma has been tried; AND

Note: Examples of systemic therapy are Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), Yervoy (ipilimumab intravenous infusion), high dose Proleukin (aldesleukin intravenous infusion); cytotoxic agents (e.g., dacarbazine, temozolomide, paclitaxel, carboplatin), imatinib, Zelboraf (vemurafenib tablets), Tafinlar (dabrafenib capsules), Mekinist (trametinib tablets).

- D) The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve up to 150 mg/m<sup>2</sup> administered as an intravenous infusion no more frequently than three times in each 28-day cycle.

---

**10. Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):

- A) Patient is  $\geq$  18 years of age; AND
- B) Patient meets ONE of the following (i or ii):
  - i. Patient meets BOTH of the following (a and b):
    - 1. Patient has persistent or recurrent disease; AND
    - 2. At least one other systemic chemotherapy regimen has been tried; OR

Note: Examples of chemotherapy are docetaxel, paclitaxel plus carboplatin.
  - ii. Patient has had a hypersensitivity reaction to paclitaxel or docetaxel; AND
- C) The medication is prescribed by or in consultation with an oncologist

**Dosing.** Approve ONE of the following (A or B):

- A) Approve up to 260 mg/m<sup>2</sup> given as an intravenous infusion no more frequently than once every 3 weeks; OR
- B) Approve up to 100 mg/m<sup>2</sup> administered as an intravenous infusion no more frequently than three times in each 28-day cycle.

---

**11. Small Bowel Adenocarcinoma.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):

- A) Patient is  $\geq$  18 years of age; AND
- B) Patient has advanced or metastatic disease; AND
- C) The medication is prescribed by or in consultation with an oncologist.

**Dosing:** Approve ONE of the following doses (A or B):

- A) Approve up to 260 mg/m<sup>2</sup> given as an intravenous infusion no more frequently than once every 3 weeks; OR
- B) Approve up to 125 mg/m<sup>2</sup> administered as an intravenous infusion no more frequently than three times in each 28-day cycle.

---

**12. Uveal Melanoma.** Approve for 1 year if the patient meets ALL of the following (A, B, and C):

- A) Patient is  $\geq$  18 years of age; AND
- B) Patient has metastatic or unresectable disease; AND
- C) The medication is prescribed by or in consultation with an oncologist.

**Dosing:** Approve up to 150 mg/m<sup>2</sup> administered as an intravenous infusion given no more frequently than three times in each 28-day cycle.

---

**13. Vaginal Cancer.** Approve for 1 year if the patient meets the following (A, B, and C):

- A) Patient is  $\geq$  18 years of age; AND
- B) The medication will be used as subsequent therapy; AND
- C) The medication is prescribed by or in consultation with an oncologist.

**Dosing.** Approve up to 125 mg/m<sup>2</sup> as an intravenous infusion no more frequently than three times in each 28-day cycle.

---

## CONDITIONS NOT RECOMMENDED FOR APPROVAL

Coverage of Abraxane is not recommended in the following situations:

1. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

## REFERENCES

1. Abraxane® suspension, intravenous infusion [prescribing information]. Summit, NJ: Celgene; August 2020.
2. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (version 4.2025 – April 17, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
3. The NCCN Drugs & Biologics Compendium. © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025. Search terms: paclitaxel, albumin bound.
4. The NCCN Non-Small Cell Lung Cancer Clinical Practice Guidelines in Oncology (version 8.2025 – August 15, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
5. The NCCN Pancreatic Adenocarcinoma Clinical Practice Guidelines in Oncology (version 2.2025 – February 3, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
6. The NCCN Melanoma: Cutaneous Clinical Practice Guidelines in Oncology (version 2.2025 – January 28, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
7. The NCCN Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer Clinical Practice Guidelines in Oncology (version 3.2025 – July 16, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
8. The NCCN Melanoma: Uveal Clinical Practice Guidelines in Oncology (version 1.2025 – February 11, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
9. The NCCN Uterine Neoplasms Clinical Practice Guidelines in Oncology (version 3.2025 – March 7, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
10. The NCCN Small Bowel Adenocarcinoma Clinical Practice Guidelines in Oncology (version 3.2025 – March 31, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
11. The NCCN Biliary Tract Cancers Clinical Practice Guidelines in Oncology (version 2.2025 – July 2, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
12. The NCCN Kaposi Sarcoma Clinical Practice Guidelines in Oncology (version 2.2026 – September 16, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
13. The NCCN Cervical Cancer Clinical Practice Guidelines in Oncology (version 4.2025 – March 24, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.

14. The NCCN Ampullary Adenocarcinoma Clinical Practice Guidelines in Oncology (version 2.2025 – January 10, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
15. The NCCN Vaginal Cancer Clinical Practice Guidelines in Oncology (version 5.2025 – February 28, 2025). © 2025 National Comprehensive Cancer Network. Available at: <http://www.nccn.org>. Accessed on October 13, 2025.
16. Shroff RT, Javle MM, Xiao L, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers. A phase 2 clinical trial. *JAMA Oncol.* 2019;5:824-830.
17. Sahai V, Catalano PJ, Zalupski MM, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma. A Phase 2 clinical trial. *JAMA Oncol.* 2018;4:1707-1712.
18. Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervical cancer: A gynecologic oncology group study. *Gynecol Oncol.* 2012;127:451-455.
19. Hersh EM, O'Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naïve patients with metastatic melanoma. *Cancer.* 2010;116:155-163.
20. Coleman RL, Brady WE, McMeekin DS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study. *Gynecol Oncol.* 2011;122(1):111-115.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	<p><b>Non-Small Cell Lung Cancer (NSCLC):</b> Added “advanced” to requirement that the patient has recurrent, advanced, or metastatic NSCLC. For the requirement that the tumor is negative or unknown for targetable mutations, added examples of targetable mutations to the Note and added “or subsequent” to the requirement that paclitaxel albumin-bound is used as initial or subsequent therapy. For requirement that paclitaxel albumin-bound is used as subsequent therapy, added “exon 19 deletion or L858R” to Epidermal growth factor receptor (EGFR) exon 19 deletion or L858R criterion and added EGFR S7681, L861Q, and/or G719X mutation as optional for approval. Added Note with examples of targeted drug therapies. Added ERBB2 (HER2) as an optional for approval.</p> <p><b>Ampullary Adenocarcinoma:</b> Added new condition of approval.</p> <p><b>Cervical Cancer:</b> Added new condition of approval.</p> <p><b>Ovarian, Fallopian Tube, or Primary Peritoneal Cancer:</b> Added “patient has had a hypersensitivity reaction to paclitaxel or docetaxel” as an additional optional for approval.</p> <p><b>Small Bowel Adenocarcinoma:</b> Added Jemperli (dostarlimab intravenous infusion) to deficient mismatch repair/microsatellite instability-high criteria.</p> <p><b>Uveal Melanoma:</b> Revised dosing to “up to 150 mg/m<sup>2</sup>” from 100 mg/m<sup>2</sup> and 260 mg/m<sup>2</sup>, and dosing frequency to no more frequently than “three times is each 28-day cycle” from no more frequently than once every 21 days.</p>	11/16/2022
Annual Revision	<b>Non-Small Cell Lung Cancer:</b> Added exon 21 to the criterion Epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R mutation.	12/06/2023
UCare P&T Review	Policy reviewed and approved by UCare P&T committee. Annual review process	09/16/2024
Early Annual Revision	<p><b>Non-Small Cell Lung Cancer:</b> Removed KRAS and added may be KRAS G12C mutation positive to the Note. Removed KRAS G12C as an option for first-line use.</p> <p><b>Biliary Tract Cancer:</b> Added patient has gallbladder cancer and medication is used as neoadjuvant therapy as new condition of approval. Added resected gross residual to requirement that the patient has unresectable, resected gross residual, or metastatic disease. Moved patient has unresectable, resected gross residual, or metastatic disease; and has gallbladder cancer, intrahepatic cholangiocarcinoma, or extrahepatic cholangiocarcinoma to an option for approval.</p> <p><b>Endometrial Carcinoma:</b> Removed “high-risk” from requirement that the patient has recurrent or metastatic disease.</p> <p><b>Melanoma:</b> Removed “advanced” from requirement that the patient has unresectable or metastatic disease.</p> <p><b>Small Bowel Adenocarcinoma:</b> Removed requirement that if the disease has deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H), the patient has progressed on Keytruda (pembrolizumab intravenous infusion), Opdivo (nivolumab intravenous infusion), or Jemperli (dostarlimab intravenous infusion).</p> <p><b>Vaginal Cancer:</b> Added new condition of approval.</p>	10/2/2024

UCare P&T Review	Policy reviewed and approved by UCare P&T committee. Annual review process	09/15/2025
Update	04/08/2025: The policy name was changed from “Oncology (Injectable) – Paclitaxel Albumin-Bound Products UM Medical Policy” to “Oncology (Injectable – Microtubule Inhibitor) – Paclitaxel Albumin-Bound Products UM Medical Policy”.	N/A
Annual Revision	<p><b>Breast Cancer:</b> In reference to triple-negative breast cancer, deleted requirement for programmed death ligand-1 (PD-L1) positive disease and also deleted requirement that the medication will be used in combination with Keytruda (pembrolizumab intravenous infusion). Also, in reference to patients with hypersensitivity reaction deleted requirements that the medication will be used for HER2 negative disease or for HER2 positive disease in combination with trastuzumab.</p> <p><b>Non-Small Cell Lung Cancer:</b> Deleted requirement the tumor is negative or unknown for targetable mutations and the note that lists examples of targetable mutations. Instead added requirement that the tumor is negative for the following actionable biomarkers: epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R, anaplastic lymphoma kinase (ALK), RET, and ROS1. Add RET rearrangement positive to the list of targetable mutations that the medication can be used as subsequent therapy. Deleted requirement that the patient has received targeted drug therapy for the specific mutation and the note with examples of targeted therapy. Deleted requirement for medication use in first line setting for tumors positive for EGFR exon 20 or ERBB2 (HER2) mutation. Also deleted requirement where the medication can be used as first-line or subsequent therapy for BRAF V600E, MET exon 14 skipping mutation, RET rearrangement or NTRK 1/2/3 gene fusion. For patients with hypersensitivity reaction deleted requirements about premedication use.</p>	10/15/2025